Table 3.

Multiple regression with levels of anti-CCP2 in serum and synovial fluid together with number of ACPA reactivities in serum, synovial fluid, immune complex fraction in serum and in synovial fluid were used as independent variables and compared with clinical and laboratory measures (only significant p values (<0.05) are shown, and underlined if the regression coefficient and T statistics were negative)

	Age	Disease duration	DAS28	Swollen joint count	Tender joint count	Global VAS	ESR	CRP	HAQ	Larsen-Dale	Time to relapse	SF PMN	SF MNC	Serum IL-6	SF IL-6	Serum TNF	SF TNF	Serum MMP3	SF MMP3	Serum PTX3	SF PTX3	Serum cathepsin L	SF cathepsin L	Serum cathepsin S	SF cathepsin S	Serum VEGF	SF VEGF
Serum anti-CCP2																0.0182								0.0034
SF anti-CCP2									0.0157	0.0438						0.0026								0.0109
No of ACPA in serum																0.0385						0.0373
No of ACPA in SF
No of ACPA in s-IC																0.0149
No of ACPA in SF IC										0.0166		0.0459			0.0007	0.048	0.0441								<0.0001		0.0377

ACPA, anti-citrullinated protein/peptide antibodies; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MNC, mononuclear cell; MMP3, matrix metalloproteinase 3; PMN, polymorphonuclear; PTX3, pentraxin 3; SF, synovial fluid; TNF, tumour necrosis factor; VAS, visual analogue scale; VEGF, vascular endothelial growth factor.